COVID-19 Outcomes in Patients with Cancer Receiving Immune Checkpoint Inhibitors: A Systematic Review [0.03%]
癌症患者接受免疫检查点抑制剂治疗后新型冠状病毒肺炎结局：系统性回顾
Juan I Ruiz,Maria A Lopez-Olivo,Yimin Geng et al.
Juan I Ruiz et al.
Introduction: Immune checkpoint inhibitors (ICIs) can cause inflammatory and immune-related adverse events (irAEs) that might worsen the course of COVID-19. We conducted a systematic review (PROSPERO ID: CRD42022307545) t...
Sarcoidosis and Airway Disease After Immune Checkpoint Inhibitor Therapy: Case Study and Review of the Literature [0.03%]
免疫检查点抑制剂治疗后的狼疮样综合征、结节性多动脉炎和新发肉芽肿性疾病：一例报告及文献回顾
Felipe Soto,Luis F Torre-Sada,Frank E Mott et al.
Felipe Soto et al.
Pulmonary toxicity from immune checkpoint inhibitor therapy is typically a severe and potentially fatal complication, but these observations are driven by the most common toxicity, pneumonitis. Rarer pulmonary immune related adverse events,...
The Contemporary Landscape and Future Directions of Intratumoral Immunotherapy [0.03%]
瘤内免疫治疗的现状和未来方向
Sebastian Brito-Orama,Rahul A Sheth
Sebastian Brito-Orama
Systemically administered immunotherapies have revolutionized the care of patients with cancer; however, for many cancer types, most patients do not exhibit objective responses. Intratumoral immunotherapy is a burgeoning strategy that is de...
Targeting Cancer Metabolism to Improve Outcomes with Immune Checkpoint Inhibitors [0.03%]
靶向肿瘤代谢以提高免疫检查点抑制剂的疗效
Zainab Fatima,Abdulrahman Abonofal,Bettzy Stephen
Zainab Fatima
Immune checkpoint inhibitors have revolutionized the treatment paradigm of several cancers. However, not all patients respond to treatment. Tumor cells reprogram metabolic pathways to facilitate growth and proliferation. This shift in metab...
Images in Immunotherapy and Precision Oncology: Angiosarcoma of the Spleen and Liver [0.03%]
免疫疗法和精准肿瘤学中的影像表现：脾脏和肝脏血管肉瘤
Anagha Deshpande,Javier Munoz,Katalin Kelemen et al.
Anagha Deshpande et al.
Primary splenic or hepatic angiosarcomas are ultra-rare and aggressive malignancies associated with poor prognosis. The mainstay treatments are surgical resection and chemotherapy. We report a case of angiosarcoma in a 50-year-old woman who...
Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer [0.03%]
复发或转移性宫颈癌接受I期试验性治疗患者的肿瘤结局预测因素分析
Ji Son,Heather Y Lin,Siqing Fu et al.
Ji Son et al.
Introduction: We aimed to identify clinical, pathologic, and treatment factors that are predictive of response and survival in patients with cervical cancer referred to phase I clinical trials. ...
Pertuzumab in Combination with Trastuzumab and Docetaxel in the Neoadjuvant Treatment for HER2-Positive Breast Cancer [0.03%]
帕妥珠单抗联合曲妥珠单抗和多西他赛新辅助治疗HER2阳性乳腺癌患者的一项随机、双盲、安慰剂对照的Ⅲ期临床试验
Cláudia Vieira,Andreia Borges,Filipa F Pereira et al.
Cláudia Vieira et al.
Introduction: This study aims to assess safety and effectiveness of pertuzumab in combination with trastuzumab and docetaxel in the neoadjuvant treatment (NeoT) of HER2-positive breast cancer. ...
Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors: The Past and the Future [0.03%]
嵌合抗原受体t细胞治疗实体瘤：过去与未来
Samer A Srour,Serkan Akin
Samer A Srour
Chimeric antigen receptor (CAR) T-cell therapy is the new standard treatment for various indications in patients with advanced hematologic malignancies. Despite the several preclinical and early phase clinical trials, the overall clinical e...
Therapeutic Targeting of DNA Damage Repair in the Era of Precision Oncology and Immune Checkpoint Inhibitors [0.03%]
精准肿瘤学和免疫检查点抑制剂时代的DNA损伤修复治疗靶向作用
Curtis A Clark,Eddy S Yang
Curtis A Clark
Cancer manifestation is a multistep process involving accumulation of various genetic and epigenetic changes that results in oncogenic "hallmarks of cancer" processes including genomic instability. Exploitation of aberrant DNA-damage respon...
Neoadjuvant Nivolumab and Ipilimumab for Nonmetastatic Renal Cell Carcinoma with Tumor Thrombus [0.03%]
用于肿瘤栓子的非转移性肾细胞癌新辅助尼伏鲁马和伊匹玛珠单抗治疗
Viraj A Master,Benjamin N Schmeusser,Adeboye O Osunkoya et al.
Viraj A Master et al.
Renal cell carcinoma with level IV tumor thrombus is a condition necessitating aggressive surgical management. Many solid organ malignancies often benefit from neoadjuvant treatments for tumor debulking and improvement of surgical outcomes....